Frankfurt
10.09.25 | 16:43
2,185 Euro
-0,68 % -0,015
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 787 | PR Newswire | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were... ► Artikel lesen | |
| Fr | Orexo AB: Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 92 | GlobeNewswire (Europe) | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared... ► Artikel lesen | |
| 29.08. | Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court | 296 | PR Newswire | UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will... ► Artikel lesen | |
| 16.07. | Orexo Q2 2025 slides: Maintains full-year outlook despite FX headwinds | 1 | Investing.com | ||
| 16.07. | Orexo hält trotz Währungsgegenwind an Jahresprognose für 2025 fest | 1 | Investing.com Deutsch | ||
| 16.07. | Orexo AB: Orexo Q2 2025 Interim Report | 144 | GlobeNewswire (Europe) | 2025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK... ► Artikel lesen | |
| 02.06. | Orexo to present clinical data for OX640 at the EAACI Congress | 250 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI... ► Artikel lesen | |
| OREXO Aktie jetzt für 0€ handeln | |||||
| 06.05. | Orexo Q1 2025 slides: stable revenue growth amid pipeline advancements | 1 | Investing.com | ||
| 06.05. | Orexo AB: Orexo Q1 2025 Interim Report | 192 | GlobeNewswire (Europe) | Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency... ► Artikel lesen | |
| 10.04. | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology | 386 | PR Newswire | The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations... ► Artikel lesen | |
| 06.02. | Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report | 173 | GlobeNewswire (Europe) | Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of... ► Artikel lesen | |
| 10.01. | Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis | 467 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical... ► Artikel lesen | |
| 17.12.24 | Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | 503 | PR Newswire | The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical... ► Artikel lesen | |
| 02.12.24 | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 396 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen | |
| 25.10.24 | Orexo initiates new study of OX640 in participants with allergic rhinitis | 363 | PR Newswire | OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery... ► Artikel lesen | |
| 24.10.24 | Orexo Interim Report Q3 2024 | 511 | PR Newswire | UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ --
Q3 2024 highlights
› Total net revenues of SEK 136.5 m (156.1)
› EBITDA of SEK -0.7 m (-9.5)
› Net earnings of SEK -41.9... ► Artikel lesen | |
| 04.10.24 | Orexo's Nomination Committee for the Annual General Meeting 2025 | 381 | PR Newswire | UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 4,230 | +0,12 % | Aurora Cannabis Inc (3): Aurora, Copeia launch English medical cannabis system | ||
| ABBVIE | 180,80 | -0,11 % | AbbVie, Atai Life Sciences und Neural Therapeutics: Deals im Milliarden-Markt für Psychedelika | ||
| TILRAY BRANDS | 0,934 | +0,71 % | Tilray Brands, Inc. - 8-K, Current Report | ||
| BRISTOL-MYERS SQUIBB | 40,460 | +0,43 % | BioNTech SE: Erste Zwischenergebnisse aus BioNTechs und BMS' globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs | Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und Patienten... ► Artikel lesen | |
| TEVA | 16,700 | -0,30 % | Teva Pharmaceutical Industries Ltd: Teva's Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy | Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New... ► Artikel lesen | |
| BAUSCH HEALTH | 6,220 | +1,72 % | Bausch Health Companies Inc.: Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage Non-Surgical System | LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics... ► Artikel lesen | |
| BIONANO GENOMICS | 4,820 | 0,00 % | Bionano Genomics bei H.C. Wainwright: Strategischer Wandel zur digitalen Pathologie | ||
| OPKO HEALTH | 1,206 | +0,35 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| JAGUAR HEALTH | 2,060 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts | Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 5, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO,... ► Artikel lesen | |
| MALLINCKRODT | - | - | Mallinckrodt plc: Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer | DUBLIN, Aug. 6, 2025 /PRNewswire/ -- Mallinckrodt plc today announced the appointment of Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.... ► Artikel lesen | |
| AVALO THERAPEUTICS | 9,760 | +3,61 % | Avalo Therapeutics: Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates | Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately... ► Artikel lesen | |
| BAYER | 28,030 | -0,73 % | Bayer-Aktie leicht im Plus (28,835 €) | Im Plus liegt aktuell die Bayer-Aktie . Zuletzt zahlten Investoren für die Aktie 28,84 Euro. Freuen können sich gegenwärtig die Aktionäre von Bayer: Das Wertpapier weist derzeit eine Verteuerung von... ► Artikel lesen | |
| NOVO NORDISK | 46,470 | +0,06 % | Hoffnung im Alzheimer-Kampf: Kann Ozempic Demenz bremsen? Novo riskiert Milliarden-Wette | © Foto: Jakub Porzycki - NurPhotoNovo Nordisk testet, ob seine Ozempic-Pille auch bei Alzheimer wirkt. Gelingt der Durchbruch, winkt ein Milliardenmarkt. Doch Experten warnen: Das Risiko ist enorm,... ► Artikel lesen | |
| MERCK KGAA | 108,60 | -0,73 % | Aktie von Merck: Kurs heute nahezu konstant (109,60 €) | An der deutschen Börse ist der Anteilsschein von Merck aktuell unauffällig. Zuletzt zahlten Investoren für das Papier 109,60 Euro. Die Wertschätzung der Börsenteilnehmer für die Merck-Aktie hat sich... ► Artikel lesen | |
| GSK | 17,270 | -0,14 % | Research and Markets: Europe Liver Disease Therapeutic Market Analysis Report 2025-2033 Featuring Abbott, Astellas, BMS, Gilead Sciences, GSK, F. Hoffman-La Roche, Merck, Novartis, Sanofi, Pfizer, Takeda - ResearchAndMarkets.com | The "Europe Liver Disease Therapeutic Market Forecast 2025" report has been added to ResearchAndMarkets.com's offering.
The Europe Liver Disease Therapeutic Market is expected to grow from US$... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.